Reviva Pharmaceuticals (NASDAQ:RVPH) Announces Quarterly Earnings Results, Beats Estimates By $0.37 EPS

Reviva Pharmaceuticals (NASDAQ:RVPH) posted its quarterly earnings data on Saturday. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.37, FiscalAI reports.

Reviva Pharmaceuticals Price Performance

NASDAQ:RVPH opened at $0.74 on Monday. Reviva Pharmaceuticals has a 1 year low of $0.67 and a 1 year high of $23.20. The stock’s fifty day moving average price is $4.27 and its two-hundred day moving average price is $7.91. The company has a market cap of $4.78 million, a P/E ratio of -0.08 and a beta of 0.10.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC increased its holdings in shares of Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after buying an additional 29,063 shares during the period. NewEdge Advisors LLC bought a new position in Reviva Pharmaceuticals during the 1st quarter worth approximately $58,000. XTX Topco Ltd grew its position in Reviva Pharmaceuticals by 63.6% during the 4th quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock worth $46,000 after acquiring an additional 63,893 shares during the last quarter. Lido Advisors LLC bought a new stake in Reviva Pharmaceuticals in the third quarter valued at approximately $37,000. Finally, Millennium Management LLC grew its holdings in shares of Reviva Pharmaceuticals by 15.0% in the third quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after purchasing an additional 223,178 shares during the last quarter. 63.18% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RVPH has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen raised Reviva Pharmaceuticals to a “sell” rating in a research note on Saturday, March 14th. Chardan Capital reiterated a “buy” rating and issued a $40.00 target price on shares of Reviva Pharmaceuticals in a report on Monday, January 5th. HC Wainwright reissued a “buy” rating and issued a $80.00 price target on shares of Reviva Pharmaceuticals in a research report on Tuesday, December 23rd. Finally, D. Boral Capital lowered shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, March 5th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $66.67.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.